​
​

Ovid Therapeutics (OVID) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

OVID Stock Forecast

Ovid Therapeutics stock forecast is as follows: an average price target of $7.33 (represents a 591.51% upside from OVID’s last price of $1.06) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

OVID Price Target

The average price target for Ovid Therapeutics (OVID) is $7.33 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $3.00. This represents a potential 591.51% upside from OVID's last price of $1.06.

OVID Analyst Ratings

Buy

According to 5 Wall Street analysts, Ovid Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for OVID stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Ovid Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 02, 2024Raghuram SelvarajuH.C. Wainwright$3.00$0.86247.95%183.02%
May 20, 2024Thomas ShraderBTIG$11.00$3.14250.32%937.74%
May 14, 2024Francois BriseboisOppenheimer$8.00$3.23147.68%654.72%
Row per page
Go to

The latest Ovid Therapeutics stock forecast, released on Jul 02, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $3.00, which represents a 247.95% increase from the stock price at the time of the forecast ($0.86), and a 183.02% increase from OVID last price ($1.06).

Ovid Therapeutics Price Target by Period

1M3M12M
# Anlaysts--3
Avg Price Target--$7.33
Last Closing Price$1.06$1.06$1.06
Upside/Downside-100.00%-100.00%591.51%

In the current month, the average price target of Ovid Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Ovid Therapeutics's last price of $1.06. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Aug 19, 2024CitigroupUnderperformUnderperformHold
Aug 19, 2024H.C. WainwrightBuyBuyHold
Jul 26, 2024CitigroupUnderperformUnderperformHold
Jul 26, 2024H.C. WainwrightBuyBuyHold
Jun 18, 2024Cowen & Co.BuyBuyHold
Jun 18, 2024B. RileyBuyBuyHold
Jun 18, 2024WedbushBuyBuyHold
Jun 18, 2024H.C. WainwrightUnderperformUnderperformHold
Jun 18, 2024OppenheimerOutperformPerformDowngrade
Jun 18, 2024H.C. WainwrightBuyBuyHold
Row per page
Go to

Ovid Therapeutics's last stock rating was published by Citigroup on Aug 19, 2024. The company gave OVID a "Underperform" rating, the same as its previous rate.

Ovid Therapeutics Financial Forecast

Ovid Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Mar 22Mar 21Dec 20Sep 20
Revenue-------------$108.97M$75.00M$66.16K$1.45M$208.38M$5.70M$6.91M
Avg Forecast$8.70M$23.00K$8.75M$73.00K$99.33K$107.67K$8.82M$124.33K$193.50K$105.50K$65.38K$52.08K$8.62M$45.83K$47.75K$18.77K$1.31M$100.53M$4.16M$100.00K
High Forecast$10.15M$26.83K$10.21M$85.17K$115.89K$125.61K$10.29M$145.06K$266.06K$123.08K$65.56K$60.75K$11.20M$53.47K$55.71K$21.89K$1.57M$100.53M$4.16M$100.00K
Low Forecast$7.25M$19.17K$7.29M$60.83K$82.78K$89.72K$7.35M$103.61K$120.94K$87.92K$65.19K$43.40K$6.89M$38.19K$39.79K$15.64K$1.05M$100.53M$4.16M$100.00K
# Analysts11111111542242228454
Surprise %-------------2377.59%1570.68%3.53%1.11%2.07%1.37%69.14%

Ovid Therapeutics's average Quarter revenue forecast for Dec 23 based on 4 analysts is $8.62M, with a low forecast of $6.89M, and a high forecast of $11.20M. OVID's average Quarter revenue forecast represents a -92.09% decrease compared to the company's last Quarter revenue of $108.97M (Sep 23).

Ovid Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Mar 22Mar 21Dec 20Sep 20
# Analysts11111111542242228454
EBITDA-------------$-12.03B$-14.17B$-14.89M$-16.19M$176.58M$-21.95M$-16.35M
Avg Forecast$-2.44M$-6.45K$-2.45M$-20.48K$-27.87K$-30.21K$-2.47M$-34.89K$-54.30K$-29.60K$-18.34K$-14.61K$-2.42M$-12.86K$-13.40K$-5.27K$-14.46M$95.96M$-1.17M$-28.05K
High Forecast$-2.03M$-5.38K$-2.05M$-17.07K$-23.23K$-25.18K$-2.06M$-29.07K$-33.94K$-24.67K$-18.29K$-12.18K$-1.93M$-10.72K$-11.16K$-4.39K$-11.57M$115.16M$-1.17M$-28.05K
Low Forecast$-2.85M$-7.53K$-2.86M$-23.90K$-32.52K$-35.25K$-2.89M$-40.70K$-74.66K$-34.54K$-18.40K$-17.05K$-3.14M$-15.00K$-15.63K$-6.14K$-17.35M$76.77M$-1.17M$-28.05K
Surprise %-------------935367.96%1057768.47%2828.01%1.12%1.84%18.78%582.64%

8 analysts predict OVID's average Quarter EBITDA for Mar 22 to be $-14.46M, with a high of $-11.57M and a low of $-17.35M. This is -108.19% lower than Ovid Therapeutics's previous annual EBITDA (Mar 21) of $176.58M.

Ovid Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Mar 22Mar 21Dec 20Sep 20
# Analysts11111111542242228454
Net Income-------------$-11.25B$-12.41B$1.52B$-16.11M$176.01M$-22.03M$-16.42M
Avg Forecast$447.15K$-8.43M$397.46K$-7.84M$-11.15M$-11.19M$-4.69M$-10.91M$-12.77M$-14.66M$-15.89M$-15.86M$-3.09M$-13.16M$-14.50M$-12.15M$-14.57M$95.65M$-21.67M$-24.85M
High Forecast$544.03K$-6.61M$483.58K$-6.14M$-8.74M$-8.77M$-3.67M$-9.46M$-11.18M$-11.48M$-12.45M$-12.42M$-2.81M$-10.31M$-11.36M$-9.52M$-11.66M$114.78M$-21.67M$-24.85M
Low Forecast$350.26K$-10.26M$311.35K$-9.54M$-13.57M$-13.62M$-5.71M$-11.64M$-14.37M$-17.83M$-19.34M$-19.30M$-3.37M$-16.01M$-17.64M$-14.78M$-17.49M$76.52M$-21.67M$-24.85M
Surprise %-------------854.93%855.85%-125.33%1.11%1.84%1.02%0.66%

Ovid Therapeutics's average Quarter net income forecast for Jun 23 is $-14.50M, with a range of $-17.64M to $-11.36M. OVID's average Quarter net income forecast represents a -100.95% decrease compared to the company's last Quarter net income of $1.52B (Mar 23).

Ovid Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Mar 22Mar 21Dec 20Sep 20
# Analysts11111111542242228454
SG&A-------------$6.81B$8.25B$8.34M$9.88M$15.58M$10.41M$7.44M
Avg Forecast$181.87M$480.93K$182.92M$1.53M$2.08M$2.25M$184.34M$2.60M$4.05M$2.21M$1.37M$1.09M$180.15M$958.36K$998.45K$392.42K$26.56M$8.47M$84.57M$2.03M
High Forecast$212.19M$561.07K$213.41M$1.78M$2.42M$2.63M$215.07M$3.03M$5.56M$2.57M$1.37M$1.27M$234.20M$1.12M$1.16M$457.80K$31.87M$10.16M$84.57M$2.03M
Low Forecast$151.56M$400.76K$152.43M$1.27M$1.73M$1.88M$153.62M$2.17M$2.53M$1.84M$1.36M$907.38K$144.12M$798.63K$832.02K$327.01K$21.25M$6.77M$84.57M$2.03M
Surprise %-------------7100.88%8261.05%21.26%0.37%1.84%0.12%3.66%

Ovid Therapeutics's average Quarter SG&A projection for Dec 23 is $180.15M, based on 4 Wall Street analysts, with a range of $144.12M to $234.20M. The forecast indicates a -97.35% fall compared to OVID last annual SG&A of $6.81B (Sep 23).

Ovid Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Mar 22Mar 21Dec 20Sep 20
# Analysts11111111542242228454
EPS-------------$-159.34$-0.18$21.60$-0.23$2.55$-0.34$-0.28
Avg Forecast$0.01$-0.12$0.01$-0.11$-0.16$-0.16$-0.07$-0.15$-0.18$-0.21$-0.22$-0.22$-0.04$-0.19$-0.20$-0.17$-0.21$1.45$-0.31$-0.35
High Forecast$0.01$-0.09$0.01$-0.09$-0.12$-0.12$-0.05$-0.13$-0.16$-0.16$-0.18$-0.18$-0.04$-0.15$-0.16$-0.13$-0.21$1.45$-0.31$-0.35
Low Forecast-$-0.14-$-0.13$-0.19$-0.19$-0.08$-0.16$-0.20$-0.25$-0.27$-0.27$-0.05$-0.23$-0.25$-0.21$-0.21$1.45$-0.31$-0.35
Surprise %-------------859.25%0.88%-126.18%1.11%1.76%1.11%0.80%

According to 2 Wall Street analysts, Ovid Therapeutics's projected average Quarter EPS for Jun 23 is $-0.20, with a low estimate of $-0.25 and a high estimate of $-0.16. This represents a -100.95% decrease compared to OVID previous annual EPS of $21.60 (Mar 23).

Ovid Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
SPROSpero Therapeutics$1.19$10.00740.34%Buy
OVIDOvid Therapeutics$1.06$7.33591.51%Buy
CTMXCytomX Therapeutics$0.87$5.73558.62%Buy
TILInstil Bio$24.76$78.25216.03%Hold
NUVBNuvation Bio$2.70$6.75150.00%Buy
ASMBAssembly Biosciences$14.72$35.50141.17%Buy
NXTCNextCure$1.29$3.00132.56%Buy
ACHLAchilles Therapeutics$1.07$2.0086.92%Buy
CNTBConnect Biopharma$0.99$1.5051.52%Buy

OVID Forecast FAQ

Is Ovid Therapeutics a good buy?

Yes, according to 5 Wall Street analysts, Ovid Therapeutics (OVID) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of OVID's total ratings.

What is OVID's price target?

Ovid Therapeutics (OVID) average price target is $7.33 with a range of $3 to $11, implying a 591.51% from its last price of $1.06. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Ovid Therapeutics stock go up soon?

According to Wall Street analysts' prediction for OVID stock, the company can go up by 591.51% (from the last price of $1.06 to the average price target of $7.33), up by 937.74% based on the highest stock price target, and up by 183.02% based on the lowest stock price target.

Can Ovid Therapeutics stock reach $2?

OVID's average twelve months analyst stock price target of $7.33 supports the claim that Ovid Therapeutics can reach $2 in the near future.

What are Ovid Therapeutics's analysts' financial forecasts?

Ovid Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $9.15M (high $10.67M, low $7.62M), average EBITDA is $-2.567M (high $-2.139M, low $-2.995M), average net income is $-37.949M (high $-30.636M, low $-44.535M), average SG&A $191.27M (high $223.15M, low $159.39M), and average EPS is $-0.535 (high $-0.432, low $-0.627). OVID's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $17.54M (high $20.47M, low $14.62M), average EBITDA is $-4.922M (high $-4.102M, low $-5.743M), average net income is $-15.43M (high $-11.721M, low $-19.139M), average SG&A $366.8M (high $427.93M, low $305.67M), and average EPS is $-0.217 (high $-0.165, low $-0.27).

Did the OVID's actual financial results beat the analysts' financial forecasts?

Based on Ovid Therapeutics's last annual report (Dec 2023), the company's revenue was $391.7M, beating the average analysts forecast of $8.73M by 4387.84%. Apple's EBITDA was $-59.281B, beating the average prediction of $-2.449M by 2420453.62%. The company's net income was $-52.339B, beating the average estimation of $-42.898M by 121908.39%. Apple's SG&A was $31.09B, beating the average forecast of $182.5M by 16933.04%. Lastly, the company's EPS was $-0.74, beating the average prediction of $-0.604 by 22.44%. In terms of the last quarterly report (Sep 2023), Ovid Therapeutics's revenue was $108.97M, beating the average analysts' forecast of $45.83K by 237658.82%. The company's EBITDA was $-12.029B, beating the average prediction of $-12.86K by 93536696.27%. Ovid Therapeutics's net income was $-11.252B, beating the average estimation of $-13.162M by 85393.10%. The company's SG&A was $6.81B, beating the average forecast of $958.36K by 709987.94%. Lastly, the company's EPS was $-159, beating the average prediction of $-0.185 by 85825.37%